Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Psychiatry

Thomas Jefferson University

2012

Pharmacokinetics

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

The Efficacy And Toxicity Of Bupropion In The Elderly, William T. Howard M.D., M.S., Julia K. Warnock M.D., Ph.D. Jan 2012

The Efficacy And Toxicity Of Bupropion In The Elderly, William T. Howard M.D., M.S., Julia K. Warnock M.D., Ph.D.

Jefferson Journal of Psychiatry

Bupropion is an antidepressant with excellent tolerability and few side effects or drug interactions. These characteristics suite it well for use both in the elderly and in the medically ill. However, early reports of seizures with bupropion therapy in patients with bulimia limited its use. The pharmacology, efficacy, toxicity, and side effect profile of both the immediate release (IR) and the recently available sustained release (SR) formulations of bupropion are reviewed. Bupropion SR is associated with a reduced seizure incidence (0.1%) compared to that found with the IR formulation (0.4%). Recent reports, however, demonstrate that the half-life of bupropion is …


Gabapentin In The Treatment Of Bipolar Disorder, Wendy M. Waits, Donald P. Hall Jr., M.D. Jan 2012

Gabapentin In The Treatment Of Bipolar Disorder, Wendy M. Waits, Donald P. Hall Jr., M.D.

Jefferson Journal of Psychiatry

Gabapentin, a relatively new anti-epileptic drug (AED), is emerging as a therapeutic option for treatment refractory and rapid-cycling bipolar illnesses. Pharmacotherapy for bipolar disorders traditionally involves valproate, carbamazapine, or lithium, drugs which are associated with numerous adverse effects. Conversely, gabapentin has an attractive pharmacokinetics profile and relatively few side effects. There are no large randomized controlled clinical trials to date examining gabapentin’s role in mood stabilization. However, informal reports have cited encouraging results in up to 80% of patients and general tolerance to side effects. These findings make the new drug a possible choice for patients who have failed to …